Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation: Successful treatment using radiation therapy plus oral bexarotene combination therapy

American Journal of Clinical Dermatology

Volumn 4, Issue 6, 2003, Pages 429-433

  Apisarnthanarax, Narin ^a   Ha, Chul S ^a   Duvic, Madeleine ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BEXAROTENE; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; ISOTRETINOIN; METHOTREXATE; VANCOMYCIN;

ADULT; ANAMNESIS; ARTICLE; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DEATH; FEMALE; FOLLICULAR CARCINOMA; FOLLOW UP; HUMAN; LABORATORY TEST; MUCINOSIS; MYCOSIS FUNGOIDES; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN EXAMINATION;

ADMINISTRATION, ORAL; ADULT; ANTICARCINOGENIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MUCINOSIS, FOLLICULAR; MYCOSIS FUNGOIDES; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 0038649659     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304060-00006     Document Type: Article

References (26)

1. Bunn P, Lamberg S. Report of the committee on staging and classification of cutaneous T-cell lymphoma. Cancer Treat Rep 1979; 63: 725-8
2. Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 34: 1022-9
3. Apisarnthanarax N, Duvic M. Therapy options in cutaneous T-cell lymphoma. Expert Rev Anticancer Ther 2001; 1: 403-20
4. Antolak JA, Cundiff JH, Ha CS. Utililization of thermoluminescent dosimetry in total skin electron beam radiotherapy of mycosis fungoides. Int J Radiat Oncol Biol Phys 1998; 40: 101-8
5. Lancer HA, Bronstein BR, Nakagawa H, et al. Follicular mucinosis: a detailed morphologic and immunopathologic study. J Am Acad Dermatol 1984; 10: 760-8
6. Hempstead RW, Ackerman AB. Follicular mucinosis: a reaction pattern in follicular epithelium. Am J Dermatopathol 1985; 7: 245-57
7. Pincus H. Alopecia mucinosa. Arch Dermatol 1957; 76: 419-26
8. Jablonska ST, Chorzelski T, Lancucki J. Mucinosis follicularis. Hautarzt 1959; 10: 27-33
9. Cerroni L, Fink-Puches R, Back B, et al. Follicular mucinosis: a critical reappraisal of clinicopathologic features and association with mycosis fungoides and Sezary syndrome. Arch Dermatol 2002; 138: 182-9
10. Sentis HJ, Willemze R, Scheffer E. Alopecia mucinosa progressing into mycosis fungoides. Am J Dermatopathol 1988; 10: 478-86
11. Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Semin Oncol 1999; 26: 276-89
12. Gibson LE, Muller SA, Leiferman KM. et al. Follicular mucinosis: clinical and histopathologic study. J Am Acad Dermatol 1989; 20: 441-6
13. Mehregan DA, Gibson LE, Muller SA. Follicular mucinosis: histopathologic review of 33 cases. Mayo Clin Proc 1991; 66: 387-90
14. Bonta MD, Tannous Z, Demierre MF, et al. Rapidly progressing mycosis fungoides presenting as follicular mucinosis. J Am Acad Dermatol 2000; 43: 635-40
15. Gilliam AC. Folliculotropic mycosis fungoides with large-cell transformation presenting as dissecting cellulitis of the scalp. J Cutan Pathol 1997; 24: 169-75
16. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002; 138: 191-8
17. Jackow CM, Papadopoulos E, Nelson B, et al. Follicular mucinosis associated with scarring alopecia, oligoclonal T-cell receptor V beta expansion, and Staphylococcus aureus: when does follicular mucinosis become mycosis fungoides? J Am Acad Dermatol 1997; 37: 828-31
18. Jackow CM, Cather JC, Hearne V, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vb gene expansion. Blood 1997; 89: 32-40
19. Diamandidou E, Colome-Grimme M, Fayad L, et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998; 92: 1150-9
20. Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9: 1057-75
21. Chinn DM, Chow S, Kim YH, et al. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 1999; 43: 951-8
22. Quiros PA, Jones GW, Kacinski BM, et al. Total skin electron beam therapy followed by adjuvant psoralen/uttraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 1997; 38: 1027-35
23. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-71
24. Duvic M, Martin A, Kim Y, et al. Phase II and III clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-93
25. Breneman D, Duvic M, Kuzel T, et al. Phase I-II trial of bexarotene gel (Targretin) for skin-directed treatment of patients with cutaneous T cell lymphoma. Arch Dermatol 2002; 138: 325-32
26. Talpur RS, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47: 672-84